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Protozoan pathogens are a highly diverse group of unicellular organisms, several of which are signiﬁcant human pathogens.
One group of protozoan pathogens includes obligate intracellular parasites such as agents of malaria, leishmaniasis, babesiosis,
and toxoplasmosis. The other group includes extracellular pathogens such as agents of giardiasis and amebiasis. An unfortunate
unifying theme for most human protozoan pathogens is that highly eﬀective treatments for them are generally lacking. We will
review targeting protozoan mitogen-activated protein kinases (MAPKs) as a novel drug discovery approach towards developing
better therapies, focusing on Plasmodia, Leishmania,a n dToxoplasma, about which the most is known.
1.GeneralPropertiesofMAPKs
Virtually all eukaryotic organisms possess MAPKs, signal
transduction molecules that regulate cell functions such as
tissue morphogenesis, cytoskeletal rearrangements, prolif-
eration, diﬀerentiation, survival, immune responses, and
adaptation/stress-response [1–3]. Encephalitozoon cuniculi is
the only example to date of a eukaryote apparently lacking
any MAPKs [4]. The MAPK superfamily, which evolved 1.0
to 1.5 billion years ago [5], comprises proline-directed ser-
ine/threoninekinases thatareclassiﬁed based ontheprimary
amino acid sequence within the catalytic domains and must
possess a[TS]XX[LIVM]XT[RK][WY]YRXPEX[LIVM]sig-
nature sequence at its core [6–8]. The phosphorylation lip
(solid underline beneath the sequence above) is required
for MAPK activation by upstream regulators and is con-
tiguous with the proline-directed (P+1) peptide binding
pocket (double underline beneath the sequence above),
conferring substrate speciﬁcity, and is capable of being
singly [(pT)XX)] or dually [(pT)X(pY)] phosphorylated in
response to particular extracellular stimuli [9]. In addition,
MAPKspossess 11subdomains[5,10]withnumeroushighly
conserved residues required for ATP binding, phosphotrans-
ferase activity, and substrate speciﬁcity [7].
MAPKs are often controlled by highly evolutionarily
conserved regulatory cascades involving sequential phos-
phorylation by three component modules consisting of
MAPK kinase kinases (MKKKs, Ste11-like kinases) and
MAPK kinases (MKKs, Ste7-like kinases), terminating in
the phosphorylation of speciﬁc MAPKs [11]. Many MAPK
cascades have recently been expanded to include a fourth
tier involving proteins aptly termed MKKKKs (Ste20-like
kinases) [12] that can either serve in a noncatalytic capacity
as ascaﬀoldtopromotepathwayassembly(andMKKKauto-
activation) or can phosphorylate speciﬁc MKKKs[13]. Once
activated, MAPKs phosphorylate a wide variety of proteins
including MAPK-activated proteinkinases and transcription
factors, ultimately resulting in changes in gene expression
[14, 15]. MAPK signaling can also have additional epigenetic
eﬀects by aﬀecting histone modiﬁcation [16].
MAPKs are grouped into subfamilies on the basis of
amino acid sequence similarity, mechanism of activation,2 Journal of Signal Transduction
and the type of MAPK cascade to which they belong. Cyclin-
dependentkinasesshare veryhighaminoacidsequenceiden-
tity with MAPKs [17] but generally lack a phosphorylation
lip. Diﬀerences in the precise amino acid composition of the
phosphorylation lip have historically been used to classify
MAPKs, as outlined below. Our phylogenetic studies [18]
have established, however, that homology between many
short strings of amino acids found in MAPKs is of equal or
greater importance when classifying MAPKs within diﬀerent
subfamilies.
Four conventional MAPK subfamilies exist, which are
also described as “typical”, that is, capable of dual phos-
phorylation [8]. These conventional MAPK groups include
the extracellular signal-regulated kinases (e.g., mammalian
ERK1 and ERK2, possessing a TEY motif at the phospho-
rylation lip, [19]), c-Jun-activated kinases (e.g., mammalian
JNK1, JNK2, and JNK3 (TPY motif) [20]), p38 stress-
response MAPKs (e.g., mammalian p38α,p 3 8 β,p 3 8 γ,a n d
p38δ (TGY motif), [21]), and mammalian ERK5 (big
MAPK-1, BMK-1 (TEY motif) [22, 23]). ERK5 is unusual
because it possesses a long carboxy-terminal extension con-
sisting of a transactivation domain and a nuclear localization
signal facilitating translocation intothe nucleusuponMAPK
activation [8]. Multiple isoforms of MAPKs often exist
within individual cells, which can either be activated by
diﬀerent MKKs or can themselves phosphorylate alternate
downstream substrates [24].Additionalphylogeneticallydis-
tinct MAPK subfamilies are deﬁned by categorizing distantly
related MAPKs including those from plants (TEY motif),
yeasts (T[EN]Y motif), and protozoans (TXY motif, where
Xi so f t e nDo rE ,b u tm a n ye x c e p t i o n se x i s t )[ 5, 18].
Several atypical MAPK subfamilies also exist, largely
representing MAPKs that can only be monophosphorylated
within their activation loops. Mammalian ERK3 [25]a n d
ERK4 [8], possessing an SEG motif in the phosphorylation
lip and an RXPR motif in the substrate binding pocket, are
representative members of one major subfamily of atypical
MAPKs, while Nemo-like kinases (NLKs, with a T[HQ]E
motif) comprise a second major atypical MAPK subfamily
[26].Greatersequencediversityexistsinthephosphorylation
lip of atypical protozoan MAPKs (most commonly TGH or
TSH motifs) compared to metazoan MAPKs, but members
of this subfamily otherwise closely resemble typical MAPKs.
Monophosphorylated human ERK2 has 10- to 100-fold
less kinase activity than dually phosphorylated ERK2 [27],
illustrating that dual phosphorylation (as is the case for typ-
ical MAPKs) achieves greater signal ampliﬁcation and range
of responses than can be achieved by monophosphorylation
(as is the case for atypical MAPKs). In addition, diﬀerent
upstream activators can preferentially phosphorylate the
threonine or tyrosine within the activation loop of typical
MAPKs, allowing signals from two diﬀerent origins to elicit
ar e s p o n s e[ 28]. Typical MAPKs are also subject to a tertiary
level of control through the expression of phosphatases
speciﬁc for either phosphothreonine or phosphotyrosine in
the activation loop [29].
Human ERK8 (homologous to rat ERK7) represents a
prototypical member of a large atypical MAPK subfamily
[30]. Although these large atypical MAPKs contain a TEY
motif capable of dual phosphorylation, activation of mam-
malian ERK8 (or ERK7) is not under the control of any
known MKK family member. Instead, they are activated by
autophosphorylation of their activation loops in response to
conformationalchangesintheircarboxy-terminalextensions
[31]—a highly unusual feature for mammalian MAPKs.
Theircarboxy-terminal extensionspossess anuclearlocaliza-
tion signal that is only exposed in the activated state, thereby
facilitatingMAPKtranslocationtothenucleus,whichinturn
regulates cell proliferation [32].
We performed ClustalW alignment [33]c o m p a r i n gt h e
amino acid sequences of representative metazoan (Homo
sapiens [21, 34], Drosophila melanogaster [35], Caenorhab-
ditis elegans [36]) and yeast (Saccharomyces cerevisiae [6])
p38 MAPKs to unique protozoan MAPKs described in this
review(Figure 1).Humanp38αwasselectedasaprototypical
MAPK for comparison for three principal reasons. First, a
plethora of p38 MAPK inhibitor drugs currently exists [37,
38].Second,thebinding speciﬁcity ofthepyridinylimidazole
p38 MAPK inhibitor SB203580 to the ATP binding pocket
of human p38α is well understood [39, 40]. Third, we have
shown that p38 MAPK inhibitors eﬀectively inhibit the in
vitro replication of protozoan parasites such as Plasmodium
falciparum (Brumlik et al., submitted), L. donovani (Brumlik
et al.,unpublished observations), and T. gondii [41]. Wehave
furtherdemonstratedthatthepyridinylimidazole p38MAPK
inhibitor RWJ67657 protects mice from lethal challenge
with T. gondii [42]. Figure 1 demonstrates that while the
overall structure ofMAPKsis highly conservedevenbetween
distantly related eukaryotes, unique features exist that could




species, of which seven are known human pathogens (in
the genera Babesia, Cryptosporidium, Cyclospora, Isospora,
Plasmodium, Sarcocystis, and Toxoplasma). There are no
reports of functional studies of MAPKs from Babesia,
Cryptosporidium, Cyclospora, Isospora, or Sarcocystis to our
knowledge. This section will thus focus on Plasmodium and
Toxoplasma.
2.1. Genus Plasmodium. The genus Plasmodium contains
four signiﬁcant human pathogens, all agents of malaria:
P .falciparum,P .vivax,P .ovale,and P.malariae. P.falciparum,
which causes the most severe form of malaria, possesses only
two MAPKs. Its Pfmap-1 represents a typical MAPK that is
predominantly expressed in gametocytes[43]w h i l eP f m a p - 2
represents an atypical MAPK (Table 1, Figure 1), which
instead possesses a TSH phosphorylation lip [44]. PfPK7,
which bears extremely limited homology to mammalian
MKK3 and MKK6 that activate host p38 MAPK, does not
appear to be a true MKK homologue. Furthermore, PfPK7
is unable to phosphorylate either recombinant Pfmap-1
or Pfmap-2 in vitro [45], suggesting that it does not




























∗ .....+ ∗ . ∗++∗ . ∗ ..+ .+ ..+ ...∗ + ∗∗++. . . . + . +. . +. . ++. ++∗∗ .++..+.
Y QNL S PVG S GAYG S V CAAFDTKT-GLRV AVKKL-SRPFQSI IHA--KRTYRELRLLKHMK
Y INLTPIGT GAYGT V CAAECTRS-GTRV A IK KF-NRPFQSI IHA--RRTYRELRLLRCMC
Y QDLQPVG S GAYGQ V SKAVVRGT-N M HV A IK KL-ARPFQSAVHA--KRTYRELRLLKHMD
Y NDLNPVGMGAFGL V CSATDTLT-SQPV A IK KI-MKPFSTAVLA--KRTYRELKLLKHLR
Y DIVQKIGK GAYGV VWK AVDK T T- HE T V A LKKI-FDAFQNATDA--QRTFREIMY L QRMD
Y KVTKALGA GAYGV V AEAVDTRT-NTTV A IK KI-SNLFVHLVDS--KRTLREITILR MLD
Y EIIH RVGK GAYGV VWK AVNR K T- NE T V A LKKI-FQAFQN DTDA--QRTFREIMF LQE L D
Y RILRHIG S GAYG I VWC A L DR R T- GKC V A LKKV-YDAFGNVQDA--QRTYREVML LQR L R
Y EIQA QLGQGAYG I VWR A L E R KH- NRV V A LKKI-YDAFQNSTDA--QRTFREIMF LHRLH
Y TLLKILGMGAYG - I ACSCLDGDTGEKV S IK KC-RDVFRDVEDG--KRVLREIDMMR F F H
Y DLVKVVG F GACGT V CSAVANGS-GERV A IK RL-SRVFGDLREG--KRI LREMEIM TSLK
Y TVTSVI GHGAYGV V CAALDDRT-FQEV A IK RV-SRVF EDL I DG--RRIWREILLLRILK
Y ETLGILG E GTYGV V VKARSRVT-GKLV A IK RF--KQTEQDEHV-RKTSSREVRMLQL L Q
F EVLNGI GY GAYGV V CAAVDLR-• -PFV A IK KVT- KVFDDLVDG--RRI LREIKLLRYLQ
Y DVL EVI G E GTYGV V FKCRDKRT-NRIV AVKQF- - KNFQTNAYV-RVAMLRELRVEQLLK
Y TVMGQLGDG SFGT V SKAQNTST-GEIV AVKKM- KQR F HSWE EC- - - LQL REIQS LRKVQ
Y TVQRFI S S G SYGA V CAGVDSEG- - I PV A IK RV- - - - FNTVSD-• -KRVLREIRLLNHFH
Y LLERIIGA G SYGV V IRARD TKS D N RLV AMKRVNKE I F EEVI LA--KRI LREIKLLAHFN
Y NVQHFVGR GAYG F V CSAVDAVT-NEPV A IK KV-MHLFDDAVDA--KRVLREVKLLAYLK
Y QI LGKKG E GTFS E V LRAQDIKT-QQYV A IK CM- KKAF K S KE QV- - NR - L REIQAVRRLQ
Y EILA QIGDGTFG S V AKAVSKKT-GQLV A IK KM- KQKF Y TWE EC- - VK - L P EVDVVRR I H
Y ILVK QIGK GGFGA V EEYTDAIT-EDNV A IK TI-PSRYVN-QES--RRLVREIDIMCFLH
Y DI LKKVGK GAYGV V FKGRCKKN-KNIV AVKKI-FGAFQNCTDA--QRTFREI IFLYELN
Y EIKHLIGR G SYGY V YLAYDKNA-NKNV A IK KV-NRMF EDL I DC--KRI LREITILNRLK
F --V K K V G S GAYGC V A- -- ----• -KKV AVKKI-GDLFRDLIDA--KRIYREIKILKELK
Y DI LQKLGK GAYG I VWK S T DR R T- NE T V A LKKI-FDAFQNATDA--QRTFREIMF LQE L A
Y EIRHLIGT G SYGHV CEAYDKLE-KRVV A IK KI-LRVFEDLIDC--KRILREIAILNRLN
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--H - E N V IG LL D V ---F T P A R S --L E E F N D V Y L V T H L M G A D L N N I V K C Q K --L T D D H V Q F
- - H-ENI I DLLDV- - - FTPNEN- -VNDI EDVYFVSMLMGADL SNILKIQR- - LNDDHIQF
--H - E N V IG LL D I F H -P H P A N G -SL E N F Q Q V Y L V T H L M D A D L N N IIR M Q H --LS D D H V Q F
--H - E N LIC L Q D I F--LS P L E D --------IY F V T E L Q G T D L H R L L Q T R P --L E K Q F V Q Y
--H - E N I V Q L V N V --- M K A E N N ------K D IY L A F E Y M E T D L H A V IR A N I--L E D IQ IR Y
--H - E N I V K LL D V ---L V P E D P ---S N F D D L Y V V F D F M Q T D M H K IIS S K Q -D LS P D H M Q Y
--H - D N IIR LF N V ---L K A E N D ------K D IY L V F E FL D S D L H Q V IK S N I--L E D I H K R Y
--H --N P FI V G IL D V -IR A A N D ------I D L Y L V F E LI E A D L T A IIR K N L --L Q R D H K R F
- -H-PNI I KLLHV- H- -RAFND- - - - - - RDI YLVFEYMETDLHVVI RANI- - LEEIHKQF
- - H-ENLLNVVNI - - - L PPLKR- EYHSF EDVYVVTPLMDVDMNVVL RSRQ- VLEESHMQY
--H - N N LIR L H H F --- M R P Q S K ---E T FE D IY L V M D LY D T D L N R IIR S R Q -K L T D E H L Q Y
ECGCRN VLRLIRV- --LPPRDP-- IMEFRDLYLVTDLYDIDLFSIIRQN K-CESIDLLRR
--H - P N V IR L E D V ---F R R E G K --------L Y L V F E FI D Q T IL Q L LE S T T R G L H R R E L R R
G-H-PN IVRL M E V GR PPAPTG A SSSAAFD DIYLVTD LM D TD LG ALLRSSQ -EIA M D Q LRF
S--E P N V T Q LLE T ---F K Q K N R -------- V Y L V M E YIP RS LL D V LE E V Q H G LPE DSL V V
--H - P N L V K L K E V ---V R E K T E --------LF M IF E Y C E K N A D E M ----- • ---E--IR S
--H - P N IL G L R D I F--V H F E E P ----A M H K L Y L V T E L M R T D L A Q V IH D Q R IVIS P Q H I Q Y
D- --DNIIGLRNI- --LTPKD P---ENFD HFYIV M DIM ETD LK Q VLRSG Q -ELTEAHIQ F
--H - P N ILS L K D L ---F K S P D P --V D T YS E L Y V V T D L M E S D M D A I LR SP R IR L A A G H G Q Y
P-H-PN IV D LV E V ---LF D RST ------G R LA LV LE L M D M SLYELIK G R K Q YL G EEK V R S
G-H-PN V VKLRE V- --IREN N E--------LFFVFEYM D GD LLG VIK KA-• -IP Y PL V K N
EAH-PH VIGYFSI- -- - -• ---- K T D E F N - V H IV M P L M K G D LF Y FIR LL-• ---------
G-H-D N IIKL M D V- --IK AK N D------N DIYLIFD FM ETD LH EVIK AD L--LEEIH KK Y
S--- D Y IIR L H D L ---IIPE D ---LL K FD E LYIV LEIA D S D L K K L FK TPI-FL T E Q H V K T
--H - E N IIN L V E I---L D P L T P ---- D FE D IY L V S D L M D T D L H R V IY S R Q -P L T P E H H Q Y
G-H-EN IVRLK N V- --LK A D N D------K DIYLVFD YM ETD LH A VIR ADI--LEEIH K Q Y
- -H-DH VVKVLDI- --VIPKD-- -VEKFDELYVVLEI ADSDFKKLFRTPV- YLTELHIKT
..+ + + + +. + . + + .. ...... ....... + + + + + + + + + . + + .. + + + ... + ...+ . + +
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LIY Q I LR G L K YIHSADIIHRDL KP S NLAV-- -- -NED CELK-I L DFGLARHTD- - - - - - -
L VYQIL R GLKYIHSADIIHRDL KP S NIAV-----NED CELK -I L DFGLARQTD- - - - - - -
L VYQIL R GLKYIHSAG VIHRDL KP S NIAV-----NED CELR -I L DFGLAR PTE- - - - -- -
F LYQILR GLKYVHSAG VIHRDL KP S NILI-----NE N C D LK -I C DFGLAR IQD- - - - -- -
I IYQLLK ALKYLHSAGIVHRDL KP S NLLL-----NSD CLLK-V A DFGLAR SLD---- ---
F VYQLL R GLKYLHSAN CVHRDL KP S NLLL-----NSD CALE-I C DLGLAR LVDDHAAKTK
I IYQ C VK ALKYLHSAEILHRDL KP S NLLL-----NSE C H MK- MA DFGLAR SIA-----AL
L TYQLL RTVAQLHAQNI I HRDL KP A NVFV-- -- - SSD CSIK-L GDFGLAR TFR- - - - --S
I IYQLLK T M KYLHSAEILHRDMKP S NLLV-----NSD CT MK-V A DFGLAR SIL-------
F VYQIL R GLKYLHSAN VAHRDL KP A NLVT-- -- -NI SCELK-I I DFGLSR SVD- - - - -- -
F MIQAF R GLHYLHSAK V MHRDL KP S NLLV-----NAD CALA-I C DFGLARDDQ- - - - - - -
I SVRVL R CLAD MHSMGIVHRDI KP S NILL R-D EKN AE-E VI-V C DFGLAR AGL-H- - ---
Y TYQLL R GIEFCHNHNV I HRDVKP E NVLI-- -- -DESGLLK-L C DFGFARQT S- - - - - - -
I AYQL MK VLVYVHSSG VIHRDL KP G NILL-----N G N C D M K -L C DFGLSRG- -- - - - -- -
L LFTIL L GIRSCHRNGI I HRDVKP E NILV R----D-D G A AS -L C DFGFCR PLP- - - - --R
I MCQTL LGVQA I HKAGFMHRDL KP E NLLI---SGD--L-VK-V A DFGLAK EIR---- ---
F MYH IL LGLHVLHEAGVVHRDLHP G NILL A---DN N D --IT -I C DFNLAR EDT- - - - - - -
F IYQ A LR ALHIIHSAG VIHRDI T P A NILV-----N T N C D LK -I C DFGLAK EEN- - - - -- -
F TLQLLC ALQYIHSAH VLHRDL KP G NLLT-----DSE C NLK-L GDFGLARGIG-H- - ---
Y MYQLL KGLDHAHRIG VFHRDI KP E NLLI-----DAE G HLK-I A DFGSCKGVY- - - - - - -
Y MRQML QALVY I HKRGYFHRDMKP E NLLIR-KEASGD EVLK-L A DFGLVK EIR---- ---
FAFQICF G LD YLHQCFI I HRDMKP DNVLVRLDITNPY MSTA LI A DMGLARDAQ-H- - - - -
I IYQLLR ALKYIHSGGLLHRDI KP S NILV-----NSE C HIK -V A DFGLAR SIS T H-----
I LYNLL L GEKFIHESGIIHRDL KP A NCLL-- -- -NQD CSVK-I C DFGLAR TIN SDKDIHI
F LYQLL L GLSFLHQADI I HRDL KP S NILV-----NLN C DIK -I C DFGLARGLN- - - - -- -
I VYQLL RAIKYMHSGELLHRDMKP S NVLL-- -- -NSECQVK-V A DFGLAR SVA-H- - SES
L LYNLLV GVKYVHSAGILHRDL KP A NCLV-- -- -NQD CSVK-V C DFGLAR TVDYPENGNS
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---------D E M TGYVA TRWYRA PEI M-L N W M H Y N Q T V DIWSVGCI MAE LLTGRTL FPGT
---------SE M TGYVA TRWYRA PEI M-L N W M H Y T Q T V DVWSVGCI LAE LIT G KTL FPGS
---------N E M TGYVA TRWYRA PEI M-L N W M H Y D Q T V DIWSVGCI MAE LITRRTL FPGT
---------P Q M TGYV S TRYYRA PEI M-LT W Q K Y D V E V DIWSAGCI FAEMIEGKPL FPGK
-------K E T L Q TDYV E TRWYRA PEI L -L G S Q R YSFAIDLWSVGCI LGE II N G K P L FPGS
ELKDAEKH DTQ M T EYVA TRWYRA PEI I -L G W P Q Y G K P V DIFSVGCI FAE LIAR KPL FPGR
SE-PSSATNPILTDYVA TRWYRS PEI L -L G C T R Y T K G V DMWAIGCI LGEMLGGSPMFPGS
GF-DNEQEFLDLTDYI A TRWYRS PEI L -V KSRAYSTA M DMWAVGCV IGEMLLGHPL FEGR
SLEGEQASRPVLTDYI A TRWYRP PEI L -L G ST R Y T K G V DMWSVGCI LAE LMLGKP I FPGR
-V -----P YSEL TDYV I TRWYRP PEL L -LE N T N YST A V DIWSVGCI FAEMYNRKPV FPGR
-V ---- M SSS D L TQYVVTRWYRP PEV L GMG SNQYT S AVDVWSLGLI FAE LMVGRAL LPGT
R L----SEPL D L TDYVVTRWYRP PEL L -L M C P-YSYPIDIW AVGCVMAE YAMQRPL FAGR
-------A R G K Y TDYVA TRWYRA PEL L -V G D V AYG KPV DVWALGCMFAE LSD G QPL FPGE
-- • -----LYSL TDYVVTRYYRA PEL L -I- M G R Y N H A I DMWSAGCI LAEMVL RRP L FTGA
-- • ------AI M TNYVA TRWYRS PEML -L G M SSY T Y A V DMWAVGAI MAE AID GEPL LPGK
-------SR PPFT EYV S TRWYRA PEL V -L H ST H Y N SP V DIW ACAVI FAE LYLCRPL FPGT
-------A D A N K THYVTHRWYRA PEL V -M QFKGFTKLVDMWSAGCVMAEMFNRKAL FRGS
------D Q G E Y M TDYVTMRWYRA PEL V -MEDKDYSVQIDVWGIGCI LGE LLGSRPL FQGK
--------D D T M TQYV F TRWYRP PEL L -L V C K H C N YSA DMWAVGCL AAEMFTGKPL FPGK
-------S K LPL T EYI S TRWYRA PEC L -LT D G Y Y N Y K M DLWSAGCV FFE IIA LFP L FPGS
-------A R PPFTDYV S TRWYRA PEL L -L Q D RFY G A A V DVWAAGCI MVE LIT M RPL FPGT
----------S D T IYI C TRYYRP PEV I -TSVSG GSPRIDIWSLGCI FYEMCTGQT L FTMR
-V--NEN K VPILTDYVA TRWYRA PEI L -L G ST H Y TE D V DMWSLGCI MGE LLCGKPL FTGN
--• - NKNLKKQLT SHVVTRWYRA PEL I -LL Q E N Y T N SIDIWSTGCI FAE LL-• -PL FPGS
--• -----D M EL TDYVVTRWYRP PEI L -IS P F C Y S K P V DLWSVGCI FAE LLGRRAL FAGK
NN- SEAGGNPVLTDYVA TRWYRA PEI L -L G STSY T K G V DMWSLGCI LGE LLSGRPI FPGT
--• ----L K R Q L TGHVVTRWYRA PEL I -LL Q E N Y TE AIDVWSIG CI FAE LL-• -PL FPGS
............ . ∗ . ∗∗∗∗∗+∗∗∗∗ +....+...+ ∗∗∗+.++ ∗+.∗+...++ ∗+++.
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DHI D- Q LKLILRLVG ----T-----P G A --ELL K KISSESA R N -----YIQ SL--T Q M P K
DHI D- Q LTRIMSVTG ----T-----PD E--EFL K KISSEE A R N -----YIR N L-P K - M T R
DHI - HQ LNL IMEMLG ----T-----P P A --EFL K KISSESA RS-----YIQ SL--PP M K G
DHV- HQ FSIITDLLG ----S-----P P K --D VIN TIC SE N T L K -----F V TSL-P H -R D P
STLN-Q LDKI IEATG ---------Q P SA --E D LE VID SPLS M N -----LLSSL-P Q -R E T
DYI -HQ LHL I LEVLG ----T-----P E K --ELL D RIAS D SA K S-----Y V L A L--K PSA P
ST M N-Q LDKIM- - -G ----G -H W E R P T P--E DIE A T ESPF AS M ----- M L D SL--Q P K T G
NTLD-Q LRLIVEAIG ---------V P S D --A D V RSL H SPELE T-----LIN SL----P T P
STTN-Q LELICSVTG --------- M P SA --A D V A A T N S Q F A H A ----- M L R DI--H C A H R
NTMD-Q LRMIAQHIG ---------K P PA- - - - - SIVEHREALE- - - - -KLNEL- - -PDGS
DYI -GQ LVMIVNLLG ----S-----P SI--D D M EFLSSE-A K A -----FILS Q -P H -R P A
DYI -HQ LQFVL- - - S ----SI----P ITG V DFIERSSSSSGLA-----N M NEIAKKYK GT
SDLD-Q LCLIM QTCG ----------P V P-----Q R L V FIF M H N ---PLY N GISFP H T DIL
NYL- SQ LALILETPG --L R G -V P Q T P EE--A A A LFE G G EE G K H ----• ----D PL T LS D Q
TEL-EQ LSLIQTRIG --------D FP AA-• --L N PL A A PP Q Q L-----R T K S M Q Q K SR R A
SESD-Q LFKICSVLG ----S-----P A P--N E W D E-G Y Q L A R R------ M N M R FP T-V A P
TFYN-Q LNKIVEVVG ----T-----P KI--E D V V M FSSPSA R D -----YL R N S-LS N V P A
DRVN-Q LDKIVDVIG ----T-----P SE--E DIN S V G SSA A Q K -----YL K K K --S H R P Q
DYIN-Q INLIVELLG ---- • -----P SKG-KKLEEYAPELRRRFDETTFYDSFDTELEEA
NELD-QVHR IHNVLG ----T P----P T EILE R L K K F G T H M D Y D ----------FP K -K Q G
NEVD-Q LFKIMSVLG ----S-----P T E---E V W A G G L R L A K K ------IR Y TFP K -V A G
- • ---Q LEVVLNTIG ----T-----P A A --E DIE R Y M PS G N A K ----LYL Q RS---A A R P
ST M N-Q LEKI IQVIG ---------K PN K --K DIE DIRSPF A E K -----IISSF--V D L K K
-- D - Q LNI I FNVIG ----T-----P P--EEDLKCITKQEVIKYIKLFPTRDGIDLSKKY
DHFD- Q LRRIVRVLG ---- -----P SKGTSNTKRKRSEAARR- - - - -FIESL-PN- SDP
ST M N-Q LERIM TLTG ---------R P SP--E D V D A V K SPF A A T----- M M ESL--PL G K V
-- D - Q LNVI FNI LG ----T-----P SE--EDIEALEKEDAKRYIRIFPKREGTDLAERF
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M N F A -N V FIG A --------N PL A -V D LLE K M L V L D S D K R I T AAQALAHAYFAQYHDPDDE
R D F K -R LF A Q A --------T P Q A -ID LLE K M L H L D P D R R P T AKEAMEHEYLAAYHDETDE
RSF K -N V F K N A --------N PL A -ID LLE K M LEL D A E K R I T AEEALSHPYLEKYAEPSVE
IPFS-E R F K T V --------EP D A -V D LLE K M L V F D P K K R I T AADALAHPYSAPYHDPTDE
K G L A -EIV P K A --------S D D A -LEL M EELL TF N PE K R A T AEKALESTFVADFHDPNDE
Q D LS-Q K FP M L---------D E A GID LL T R M L T L D PL K R I T VNECL SHPYFEGIHDESDE
K A LS-EIY P N A --------P A D A -L D LL K K LL Q F N P N K R L T AEQALEHPYLSKFHDPATE
LIFS-PL V G N K -----SL K D SE A T-D L M M K LIV F N P K R R L S AVEALQHPYVAPFLQPGEL
R TF A -ELLPSA --------SA D A -L D LIE R F M R F N P N R R I S AAEALEHPYVAAFHRPDEE
L NIP-K L V P G L------A G N T E G -ID FLS K M W T L D PS K R P T AADMLAHPYLAHLHDEEDE
LSF R-D LFS M A --------T EE A -T D LLS K LL V F H P A R R L T AKQVMEHPYFSKYRDAAEE
R PLP-Q LLS K L--------P R D G -LEL V T E M L A FEP N K R I T AQEALKHPFFS SVGGPDCK
Y T L K -E R Y H R E--------S N D W -LEFLSS C L H T D P A Q R L T CTELMELPYFTRDGFRDRY
VHSQ- VLFHSTLFGFKVDVP I S LGI - L I AKLL S FDPRKR P T ALEALRDPFFWPLYDSRDE
SDV-• -RYGGR- - - - - - - - IAKAGLNLLHGLLRIDAAER I T VEEALGHPYFDSVRGRFDA
T PL R-HIL T T A --------PP A A -V D L M A Q M L R F N P A E R P T ATQCLQHPYFTGSGGSSAL
R A W T-A V V P T A --------D P V A -L D LIA K M LEF N P Q R R I S TEQALRHPYFESLFDPLDL
A D W R-Q R Y P K A --------SPE A -L D LL R H M L V F N P K R R I T VLQAMRHPFLEQLHDDADD
IA VE G AIIA RPRP H PPEEYYAEF-V DFIFGLLC Y N PA K R R T AKES IAHAWLSDVRGPQET
T G L G -K LLP H V --------SA E A -L D L M K K LL T Y D EE Q R C T AKEALRHAYFSKLREADKK
S G L A -Q A LPS H -------IPLP A -L D LL R Q M L V Y D P K V R L T AEQCLQHPFFNVGIDECNA
SQ LR-Q LIE Q N W IL H TSA D EKEK W IDLITR C V AFFPE Q R P T AQQLCQHQLFRNYNVFYGS
K N L K -DIC Y K A --------S N ES-L D LLE K LL Q F N PS K R I S AENALKHKYVEEFHSI IDE
-----------------SSIS K E GID LLES M L R F N A Q K R I T IDKALSHPYLKDVRKENLE
Y K LE-D LFP D A --------S K A A -L D LLS N LL TF D P A K R I T VQEALRHEYFEGLHSVEDE
K N F K -D A FP N A --------SPE A -L D LL K Q LL Q F N P N K R I S AEKGLEHPYVRQFHSPEDE
-----------------P ASSA D AIH LL K R M L V F N P N K R I T INECLAHPFFKEVRIAEVE




























Figure 1: Continued.6 Journal of Signal Transduction
PVADPY-DQSFESRDLL IDEWKSLTYDEVI SFVPPPLDQE
P IAEEM- DLNDDVRADT IDEWKKI IWEE I SDFQKNVAFAD
QTSPPY-D HSFED M DLPVDK W KELIYKEVTNFKPPPSYAQ
PVADAKFD W HFNDADLPVDTWRVM MYSEILDFHKIGGSDGQ
PSAPGKITIPITD N HKYSIN NYRGSLYVEIM RKYPQ N
PVYTGQPLEL F FEKYELTKPLLEMCF LNEARKFHPDELKDEVAKRAKALG I PE SVWM
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†C-terminal extension is only present on splice variant of tgMAPK1 containing exon 8.
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Figure 1: ClustalW alignment of representative MAPKs of diverse evolutionary origin, with each of the 11 subdomains indicated (Roman
numerals). Conserved acidic residues within the ED site (subdomain VII) and common docking (CD) domain, which immediately follows
subdomain XI, have been underlined. The ﬁrst four sequences represent p38 MAPKs of metazoan and yeast origin and are boxed as
reference sequences to which other protozoan MAPKs can be compared. Invariant MAPK residues (within allowed substitution groups) are
highlightedinblackanddenotedbyanasterisk.Highlyconservedresidues(>80%conservation)arehighlightedingreyanddenotedbyaplus
sign.In the absence ofgrey shading,plus signs indicate residues conserved in the majorityofalignedsequences. Allowed substitution groups
include acidic/amide (DE, DN, EQ), aliphatic (LIVM), aromatic (FYW), basic (KR), and hydroxyl/polar residues (STG). The positions of
insertion sequences removed prior to ClustalW alignment are indicated by ﬁlled circles. White triangles denote the position of the TX[XY]
phosphorylationlip. Two letter abbreviations precede the name of each MAPK sequence, indicating the genus and species of origin for each
MAPK. CE: Caenorhabditis elegans;D M :Drosophila melanogaster;E H :Entamoeba histolytica;G I :Giardia intestinalis;H S :Homo sapiens;
LMa: Leishmania major;P F :Plasmodium falciparum;S C :Saccharomyces cerevisiae;T G :Toxoplasma gondii. Accession numbers of all aligned
sequences are listed in Tables 1 and 2.
in Plasmodium.M o r e o v e r ,n oP. falciparum MKK genes
have been identiﬁed, suggesting that P. falciparum MAPK
signaling does not utilize typical MAPK cascades [46]. P.
falciparum Pfmap-2 is instead activated by Pfnek-1, a never-
in-mitosis/Aspergillus- (NIMA-) related kinase [47]. Since
homology amongst MKKs and MKKKs is much lower
than that for members of the MAPK superfamily, it is
conceivable that genes encoding these proteins exist but have
simply not been annotated as such in the P. falciparum
genome.
Pfmap-1 is neither required for schizogony nor game-
tocytogenesis in human erythrocytes cultured in vitro,
nor for gametogenesis and/or sporogony in the mosquito
vector [48]. However, Pfmap-2 protein levels are elevated
in pfmap-1 knockout parasites, suggesting that Pfmap-1
fulﬁlls an important function necessitating compensatory
adaptation in parasites lacking this enzyme. Pfmap-2 is
essential for the completion ofthe P. falciparum asexual cycle
[48]. Functional characterizations of MAPKs from P. vivax,
P. ovale, andP. malaria, theotherPlasmodiumspeciescausing
malaria, have yet to be reported to our knowledge.
2.2. Genus Toxoplasma. T. gondii, the sole member of
the genus Toxoplasma, can cause signiﬁcant morbidity or
mortality in hosts with compromised cellular immunity.
Like P. falciparum, T. gondii appears to be another proto-
zoan parasite that lacks typical MAPK activation cascades.
Preliminary examination of the T. gondii genome suggests
t h a ti te n c o d e sf o u rM A P K s .H o w e v e r ,t h eT G M E 4 9021550
locus (situated on chromosome II) lacks coding sequences
corresponding to several essential MAPK motifs (including
an incomplete MAPK signature sequence), thereby disqual-
ifying it as a functional MAPK gene. Of the remaining
three MAPK genes (Table 1, Figure 1), we have cloned and
sequenced both the genes encoding tgMAPK1,s i t u a t e do n
chromosome XI [50], and tgMAPK2 (chromosome VIII;Journal of Signal Transduction 7
Table 1: Non-Trypanosomatid mitogen-activated protein kinases discussed in this review.
Organism MAPK Accession no. Phosphorylation
lip Classiﬁcation Function References
Caenorhabditis elegans p38 AAB00664 TGY Typical Stress-response [36]
Drosophila melanogaster p38α AF035547 TGY Typical Stress-response [35]
Entamoeba histolytica EhMAPK AY460178 TDY Typical ?
Giardia intestinalis ERK1 AY149274 TEY Typical Encystation [49]
ERK2 AY149275 TDY Typical Encystation [49]
Homo sapiens p38α Q16539 TGY Typical Stress-response [21, 34]
Plasmodium falciparum Pfmap-1 Q94656 TDY Typical ?
Pfmap-2 Q25917 TSH Atypical Essential for
diﬀerentiation [48]
Saccharomyces cerevisiae Hog1 AAA34680 TGY Typical Stress-response [6]
Toxoplasma gondii
TgMAPK1




TgMAPK2 DQ115400 TDY Typical ?
TgMAPK3 XP 0022369585 TGH Atypical ?
†Brumlik et al., submitted.
[18]). We have also sequenced the third MAPK gene,
tgMAPK3 (chromosome Ib).
TgMAPK1 is a critical virulence determinant during
acute T. gondii infection (Brumlik et al., submitted).
By expressing it in Hog1-deﬁcient yeast lacking its own
stress-response MAPK, we restored yeast ability to grow
under osmotic stress [50], providing evidence for this
MAPK’s role as a stress-response MAPK. Since TgMAPK1
expression aﬀects tachyzoite/bradyzoite stage diﬀerentiation
(manuscript in preparation), we renamed it “BARKY”
(bradyzoite antigen regulator, kinase Y).
BARKYis a typical MAPK based on conventionalcriteria
[50] although it possesses three insertion sequences. Using
mass spectroscopy, we conﬁrmed the presence of a 34 amino
acid insert situated between the GXGXXGXV motif (subdo-
main I) and the invariant lysine residue within the VAXK
motifofsubdomainII,aregionresponsibleforanchoringthe
nontransferable α-andβ-phosphatesofATPduringcatalysis.
BARKY is also predicted to encode a 93 amino acid insert
situated between the DFGLAR motif that interacts with the
Mg++ boundtoATPandthephosphorylationlip,whichlinks
the proline-directed peptide binding pocket in an extended
conformation following phosphorylation of its activation
loop (subdomains VII and VIII, resp.). Finally, using mass
spectroscopy, we identiﬁed a 20 amino acid insert between
subdomains IX and X.
Phylogenetic analysis demonstrates thatT. gondii BARKY
most closely resembles Cryptosporidium hominis MAPK
(with 52% amino acid sequence identity across all 11 of the
MAPK subdomains), with a corresponding homologue in
C. parvum. Noothercloselyrelated MAPK homologueswere
identiﬁed either within or outside the phylum Apicomplexa
a tt h et i m eo fp u b l i c a t i o n[ 18].
Alternative splicing within exons 3-4 and exons 7-8
of the BARKY gene results in multiple BARKY isoforms,
producing protein variants that could diﬀerentially respond
to upstream signals or have altered substrate speciﬁcity. In
support, we have detected 50, 58, and ∼130kDa proteins
in T. gondii tachyzoite cell-free extracts by Western blotting.
We have also employed mass spectroscopy to detect peptide
fragments that conﬁrm the existence of the full length
(130kDa) BARKY protein in tachyzoites grown in vitro.
We cannot exclude the possibility that the smaller forms of
the protein result from proteolytic degradation, but reverse
transcriptase-polymerase chain reaction has demonstrated
the presence of BARKY transcripts with a stop codon-
situated 84 nucleotides into exon 7, as well as an alternative
BARKY splicevariant encodingexon8thatadds a766amino
acid extension to the carboxy-terminus (Brumlik et al.,
unpublished observations). These featuresare reminiscent of
extensions identiﬁed in many Leishmania MAPKs [51].
There are no reported functional data for T. gondii
TgMAPK2 but it is expressed in T. gondii tachyzoites at
the expected molecular weight of 73kDa (Brumlik et al.,
unpublished observations). Phylogenetic analysis places this
MAPK in a group of closely related Apicomplexan MAPKs
which includes Cryptosporidium hominis MAPK1, P. falci-
parum Pfmap-1, and Theileria annulata MAPK (all sharing
roughly 70% amino acid sequence identity across all 11 of
theMAPK subdomains).TgMAPK2shares signiﬁcant amino
acidsequenceidentitywithMAPKsfromnon-Apicomplexan
protozoans including L. mexicana LmxMPK2 (62%) and
Trypanosoma brucei TbMAPK2 (62%), each possessing a
typical TDY phosphorylation lip. The deduced amino acid
sequence of TgMAPK2 shares 55% identity with human
ERK8 across all 11 MAPK subdomains, demonstrating the
remarkable evolutionary conservation of this MAPK sub-
family member. In addition, T. gondii TgMAPK2 possesses
multiple copies of a VSSSHHG repeat in its carboxy-
terminal extension, theexact number of repeats being strain-
dependent [18]. While the role of this repeat remains
unknown, it is striking that P. falciparum Pfmap-1 possesses8 Journal of Signal Transduction
an analogous series of imperfect KKYVD[GSE][GSL]N
repeats in its carboxy-terminal extension [43]. Short amino
acid repeats often facilitate oligomerization or serve as
contact points for protein-protein interactions. Interestingly,
TgMAPK2 is also predicted to possess a nuclear localization
signal within its carboxy-terminal extension.
T. gondii TgMAPK3 is predicted to be an atypical 63kDa
MAPK with a TGH phosphorylation lip. It shares signif-
icant amino acid sequence identity with several Apicom-
plexan MAPKs such as Cryptosporidium hominis MAPK2
(67%), P. falciparum Pfmap-2 (58%), and Theileria annulata
MAPK2 (50%), with low amino acid sequence identity to
non-Apicomplexan MAPKs [18].
3.PhylumSarcomastigophora
3.1. Trypanosomatid MAPKs. Trypanosomatids (members
of the family Trypanosomatidae) are a diverse group of pro-
tozoan parasites of which two genera are human pathogens:
Trypanosoma and Leishmania.
3.1.1. Genus Leishmania. Several diﬀerent Leishmania
species cause human disease of varying clinical presentation
and severity, of which L. major generally causes the most
serious illnesses. Genome sequencing has identiﬁed 15
putative complete MAPK genes in L. major (Table 2), the
alignments of which are shown in Figure 1.T w op a r t i a lL.
major MAPK genes have also been identiﬁed (LmjF03.0210
and LmjF13.07800) [52] but have been excluded from
further consideration because they lack the coding region
for the complete MAPK signature sequence. All 15 L. major
MAPK homologues have also been identiﬁed in L. mexicana
(Table 2), L. infantum,a n dL. brasiliensis [52].
Each of the 15 unique Leishmania MAPKs (Figure 1)i sa
typical MAPK by the classical deﬁnition (i.e., the activation
loop is comprised of a TXY motif). The majority of these
MAPKs possess carboxy-terminal extensions (Figure 1),
someofthemover1000aminoacidslong(asforLmaMPK8).
This region may be analogousto thecorresponding region of
human ERK5 or ERK8, each of which possesses a C-terminal
transactivation domain and nuclear localization signal [22,
23]. LmaMPK6, 7, and 8 are predicted to contain nuclear
localizationsignalswithin theircarboxy-terminalextensions,
making them even more closely resemble human ERK5 and
ERK8, as well as T. gondii TgMAPK2.
Deletion analysis of the genes encoding L. mexicana
LmxMPK1 and LmxMPK2 demonstrates that both are
essential for amastigote (bloodstream stage) survival [52,
53]. L. mexicana LmxMPK4 is essential to both promastigote
(sandﬂy stage) and amastigote forms [58]a n di sp h o s -
phorylated on T190 and Y192 of its phosphorylation lip
by the MKK LmxMKK5 [64]. Overexpression of L. major
LmaMPK4, 7, or 10 (homologues of LmxMPK4, 7, and 10,
resp.) causes stage-speciﬁc induction of phosphotransferase
activity. Moreover, LmaMPK7 activation speciﬁcally regu-
lates parasite growth [62]. In each case, kinase activity was
low or absent in cell-free extracts from promastigotes but
signiﬁcantly increased after exposure to pH 5.5 and 34◦C.,
which simulates the stress encountered by the parasite in
the acidiﬁed phagolysosome upon invasion of macrophages
[59]. L. mexicana LmxPK4 is an MKK that controls parasite
diﬀerentiation [65] and thus represents a potential upstream
a c t i v a t o ro fa tl e a s to n eo ft h eM A P K sa ﬀecting stage
diﬀerentiation.
Several L. mexicana MAPKs regulate ﬂagellar length,
many of which possess carboxy-terminal extensions [66].
Deletion mutants for LmxMPK3 had shortened ﬂagella and
overexpression of LmxMPK3 in the deletion background
complemented this defect [56, 57]. Deletion mutants for
LmxMPK9, LmxMPK13, or LmxMPK14 generated pro-
mastigotes with elongated ﬂagella, an eﬀe c tt h a tc o u l db e
reversed by overexpressing these MAPKs in null mutants
[57, 63]. LmxMPK13 is the homologue of LF4 from the
protozoan microalga Chlamydomonas reinhardtii,w h i c ha l s o
regulates ﬂagellar length [67]. L. mexicana LmxMKK is the
MAPKK responsible for regulating ﬂagellar length [68]a n d
activates LmxMPK3 [56]a n dp e r h a p sa ﬀects other MAPKs
regulating ﬂagellar length.
Analysis of the L. mexicana genome has identiﬁed two
additional putative MKK genes in addition to L. mexicana
lmxPK4, lmxMKK, and lmxMKK5 for which functions have
yet to be determined. L. mexicana also putatively encodes 23
MKKKs and a single MKKKK [51], the functions of which
remain unknown.
3.1.2. Genus Trypanosoma. Subspecies of T. brucei cause
African sleeping sickness, whereas T. cruzi causes New World
trypanosomiasis (Chagas disease). Genomic sequencing has
identiﬁed 13 MAPK genes in T. brucei, each of which has at
least one, but often two virtually identical copies of MAPK
homologues in T. cruzi (with each copy having greater than
99% amino acid sequence identity to the other (Table 2))
[51, 52]. Homologous T. brucei or T. cruzi MAPK domains
are ∼90% identical to each other and each has a single
corresponding homologue in Leishmania spp. (sharing over
80% amino acid sequence identity across the 11 MAPK
subdomains). LmxMPK7 and LmxMPK8 are the only two
Leishmania MAPKs that lack homologues in either T. brucei
or T. cruzi. Thus we exclusively used the L. major MAPK
sequences(LmaMPK1-15)forClustalWalignment,reducing
redundant examples of highly homologous MAPKs in the
analysis.
Although all Trypanosoma MAPKs possess a classical
TXY motif, a feature also conserved in all Leishmania
MAPK homologues (Table 2), the central amino acid in
the TXY motif varies between MAPK homologues from
diﬀerent Trypanosomatid species (Table 2) and thus is not
as evolutionarily constrained as in mammalian MAPKs.
T. brucei/cruzi MPK10 (accession nos. Q580Z7/
Q4D4Q4) and MPK11 (accession nos. Q389D8/Q4CZQ7)
have not yet been oﬃcially named (see Table 2). Regardless,
these MAPKs (and their Leishmania MAPK homologues)
are exceptional in possessing a MAPK signature sequence
that deviates with respect to the precise position of the
threonine in the proline-directed (P+1) peptide binding
pocket (see Figure 1, center of subdomain VIII, residues
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of the proline-directed peptide binding pocket relative to
the phosphorylation lip, perhaps placing these MAPKs in
a separate subfamily.
KFR1 (KSS1- and FUS3-related kinase 1), the T. brucei
homologue of L. mexicana LmxMPK1, mediates interferon-
γ-induced amastigote proliferation and phosphorylates ser-
ine residues on host histone H1, myelin basic protein,
and β-casein [54, 55]. T. brucei TbECK1, which is the
trypanosome homologue of L. mexicana LmxMPK6, pos-
sesses a carboxy-terminal extension that regulates kinase
activity in all life cycle stages. Expression of a truncated
TbECK1 protein lacking large parts of this extension caused
T. brucei to grow slowly with abnormal morphology [61].
T. brucei procyclic forms lacking TbMAPK5, the homologue
of L. mexicana LmxMPK5, likewise showed impaired dif-
ferentiation into the bloodstream form [60]. TbMAPK2,
the T. brucei homologue of LmxMPK4, regulates cell cycle
progression from the procyclic (tsetse ﬂy midgut) form to
the bloodstream form [69]. TbMAPK5 controls T. brucei
diﬀerentiation[60]. Nofunctional studies ofT. cruzi MAPKs
have been published to date to our knowledge.
Phylogenetic analysis of T. brucei and T. cruzi suggests
a single gene orthologous to the ﬁve putative MKK genes
in L. major [51]. Only about one-third of the putative
L. major MKKK genes have phylogenetic branching patterns
consistentwiththeexistenceoforthologousgenesinT. brucei
and T. cruzi [51]. In most cases, L. major and T. brucei
MKKK genes appear to be paralogues, having arisen from
gene duplication events [51], suggesting signiﬁcant evolu-
tionary divergence in the circuitry of signaling cascades in
Trypanosomatids. Three unique MKKKK genes have been
identiﬁedin T. cruzi andtwoinT. brucei [51].Functionshave
yet to be ascribed to any of these putative upstream MAPK
activators.
3.2. Other Sarcomastigophora. Two MAPKs have been iden-
tiﬁed and characterized in the protozoan intestinal parasite
Giardia lamblia,E R K 1a n dE R K 2( Table 1, Figure 1), each of
which plays distinct roles in encystation [49]. In addition,
one MAPK gene has been identiﬁed in the Trichomonas
vaginalis genome [70]. However, functional studies have yet
to be performed on MAPKs from either parasite.
3.3. Subphylum Sarcodina (the Amoebae). This subphylum
of amoebas contains three human pathogenic genera: Enta-
moeba, Naegleria, and Acanthamoeba.T h eE. histolytica
EhMAPK gene encodes a putative MAPK with signiﬁcant
homology to human ERK8 [71]. We are not aware of any
further MAPK analyses in this genus or of any reports of
MAPK genes or function in Naegleria or Acanthamoeba.
4.Protozoan MAPKsasTherapeuticTargets
MAPKs direct many functions critical to pathogen home-
ostasis and survival, including proliferation [62], diﬀerenti-
ation [52, 53], regulation of cytoskeletal features such as the
biosynthesisofﬂagella[56,57,63],andstress-responses [50].
Because protozoan MAPKs share many common structural
features and are vastly more closely related to each other
than to human MAPKs [18, 72], it should be possible to
designdrugsspeciﬁcallyorpreferentiallytargetingprotozoan
MAPKs. For example, Leishmania mexicana LmxMPK1 and
LmxMPK2 are essential MAPKs required for diﬀerentia-
tion [52, 53], with corresponding homologues in other
Leishmania species and in T. brucei and T. cruzi [51],
but bearing scant resemblance to human MAPKs, mak-
ing them excellent candidates for drug development [72].
Speciﬁcally targeting these MAPKs could have far reaching
therapeutic potential since one drug could be used to treat
a broad range of Trypanosomatid infections based on the
high degree of homology between Trypanosomatid MAPKs
[51].
P. falciparum Pfmap-2 is likewise an excellent druggable
target as this MAPK is essential for the parasite to complete
asexual replication in infected human erythrocytes [48]
and it is highly dissimilar to human MAPKs. Although we
have yet to determine which of the T. gondii MAPKs are
essential to parasite survival, reducing BARKY expression
dramatically impairs parasite virulence (Brumlik et al., sub-
mitted), making BARKY a useful target for MAPK inhibitor
drugs.
Agentsinterfering withthefunctionofMAPKsthataﬀect
stage diﬀerentiation, such as T. gondii BARKY, or aﬀect
parasite growth, such as L. major LmaMPK7 or T. brucei
TbECK1,likelywouldbe useful antiparasitic agents. T. brucei
KFR1 is an interesting MAPK target, as it regulates eﬀects of
the host immune response (interferon-γ-induced amastigote
proliferation) and could be considered in combination with
an immune strategy. L. mexicana LmxMPK1 is homologous
to KFR1 and could mediate similar eﬀects, being a useful
drug discovery target in this respect. Agents impairing
the function of MAPKs controlling ﬂagellar development
or function, such as LmxMPK3, LmxMPK9, LmxMPK13,
or LmxMPK14, could inhibit parasite dissemination and
might be useful alone, or in combination with parasiticidal
agents.
Our work with T. gondii BARKY demonstrates multiple
MAPK splice variants that can occur naturally in parasites. A
better understanding of the function of these splice variants
could help develop agents speciﬁcally targeting variants rele-
vant todisease pathogenesis. Likewise,ourgenomicanalyses,
and those of others, have demonstrated unusual repeat
motifs in several protozoan parasite MAPKs (including in
T. gondii and Plasmodium species) encoding large numbers
of potential phosphorylation sites. An understanding of the
functional signiﬁcance of these motifs could help develop
useful antiparasitic agents.Giventherelativelyuniquenature
of the phosphorylation site repeat motifs, these sites possibly
could lead to highly parasite-speciﬁc drugs.
Protozoan MAPKs need not subserve critical functions
to be useful drug discovery targets. Forexample, L. mexicana
LmxMPK6 aﬀects parasite morphology (which has indirect
consequences on its growth rate following infection) and
hashomologuesinrelateddisease-causing Trypanosomatids.
Drugs impairing LmxMPK6 function could be used in
conjugation with existing anti-Leishmania therapies to boost
their eﬃcacy and could have broad-spectrum eﬀects.12 Journal of Signal Transduction
Upstream components of the MAPK cascades such
as the MKKs or MKKKs in pathogenic protozoan par-
asites are also potentially useful drug discovery targets.
For example, the L. mexicana MKK, LmxPK4, controls
parasite diﬀerentiation and thus is an excellent candidate.
Because protozoan MKKs and MKKKs are even more
distantly related to mammalian counterparts than MAPKs,
a further potential advantage to this approach is that drugs
inhibiting parasite MKK function could be less likely to have
undesirable side-eﬀects compared to drugs targeting speciﬁc
MAPKs.
A potential disadvantage to targeting upstream MAPK
regulators relates to our incomplete understanding of how
they function. For example, MAPKs such as human p38α
arecapableofMKK-independentactivationandcanundergo
autophosphorylationin thepresenceoftransforming growth
factor-β-activated protein kinase 1[73].In thiscase, it would
not be possible to block p38α activation by targeting the
conventional upstream MKKK and MKK components of the
p38 MAPK cascade.
Many protozoan MAPKspossess vestiges of the common
docking (CD) domain and ED site (Figure 1)—surface-
exposed acidic residues in human p38α MAPK that facilitate
binding to upstream and downstream MAPK partners [74,
75]. D313,D 315,a n dD 316 comprise the CD domain in human
p38α MAPK. This region acts in concert with the ED161 site
to bind to short strings of 2–5 basic amino acids situated on
proteins with which p38α interacts [74]. Protozoan MAPKs
lacking a conserved CD domain (e.g., Leishmania major
LMaMPK9 and 15) and/or ED site (e.g., Leishmania major
LMaMPK3, 7, 9, 11, 15, and T. gondii TgMAPK1) are prime
candidates for drug development since these domains have
diverged considerably from their corresponding mammalian
counterparts.
In addition, the highly variable carboxy-terminal exten-
sions, which are present in over half the protozoan MAPKs
shown in Figure 1,are excellenttargetsfordrugdevelopment
owing to their unique structures. Drugs targeted to these
extensions would have a low probability of aﬀecting mam-
malian MAPKs.
SB203580 is a pyridinylimidazole competitive ATP
inhibitor aﬀecting human p38 MAPK phosphotransferase
activity through hydrogen bonding between its pyridine
ring nitrogen and the MAPK backbone amide of M109
in the THLM109 motif (subdomain V; Figure 1)[ 39]. A
second critical hydrogen bond occurs between a nitrogen
atom on the imidazole ring and the invariant lysine in the
VAXK53 motif (subdomain II). Finally, the ﬂuorophenyl ring
of SB203580 interacts with the hydrophobic environment
created by T106 and H107[39].
Because SB203580 is much smaller than ATP (as are
all pyridinylimidazole p38 MAPK inhibitors), it does not
fully occupy this region, leaving two large hydrophobic
pockets on either side of the pyridine ring [39]. By
designing novel pyridinylimidazoles or structurally related
pharmacophores that properly ﬁll the ATP binding pocket
of pertinent protozoan MAPKs, it could be possible to
develop novel antiparasitic agents that are more potent
and speciﬁc than existing drugs. Such drugs will be less
likely to have unintended consequences on host p38 MAPK,
which is a potential drawback of several existing p38 MAPK
inhibitors.
Recent molecular modeling studies using competitive
ATP inhibitors against LCRK3 in L. donovani, a cyclin-
dependent kinase that is a distant relative of the MAPK
superfamily, indicate that such compounds could have
signiﬁcant inhibitory activity against L. donovani LCRK3
[76]. Our work has shown that the human p38 MAPK
inhibitors RWJ67657, RWJ68198, and SB203580reduced the
replication of L. donovani promastigotes in axenic culture.
Moreover, SB203580 eﬀectively inhibited the replication of
the bloodstream stage cultured ex vivo (Brumlik et al.,
unpublished observations).
X-ray crystallographic studies of human p38α MAPK
complexed with ATP have demonstrated that the THLM109
motif in the center of subdomain V (Figure 1)f o r m st w o
critical hydrogen bonds with the adenosine moiety [77].
Based on our ClustalW alignment, many other amino acids
can evidently serve this same purpose in other MAPKs
(Figure 1; subdomain V), although the binding aﬃnity of
ATP(and competitive ATPinhibitordrugs) couldbeaﬀected
by such diﬀerences. Structural studies have further shown
that the invariant GXGXXGXV38 motif in subdomain I
coordinates thenontransferable α-a n dβ-phosphates of ATP,
while catalytic transfer of the γ-phosphate is mediated by
hydrogen bonding between an essential lysine in the VAXK53
motif (subdomain II), the RE68 motif in subdomain III, and
the underlined residues in the HRD168XK170PXN173 motif
(subdomain VIb) [78]. Thus, to design novel competitive
ATP inhibitors against protozoan MAPKs, one must not
only account for the invariant residues comprising the ATP
binding site in all MAPKs but also pay particular attention
to the permissible structural changes in subdomain V of
protozoan MAPKs that speciﬁcally aﬀect the binding of
competitive ATP inhibitors.
We have shown that SB203580 [50]a n da n o t h e r
pyridinylimidazole human p38 MAPK inhibitor, RWJ67657,
signiﬁcantly inhibit BARKY autophosphorylation (Brumlik
et al., unpublished observations). These agents reduced T.
gondii proliferation in vitro [41] and treated otherwise fatal
T. gondii infection in mice [42]. We further assessed the
eﬃcacyoftwohumanp38MAPKinhibitorstotreatparasitic
infections and showed that RWJ67657 and the pyrroloben-
zimidazole RWJ68198 eﬀectively blocked the replication
of P. falciparum cultured in human erythrocytes ex vivo.
Drug treatment resulted in trophozoites that were markedly
diminished in size (Brumlik et al., submitted).
We demonstrated that RWJ67657 protected mice from
otherwise fatal infection with the protozoan Encephalitozoon
cuniculi [42] although it encodes no known MAPKs. Inhi-
bition of host p38 MAPK could improve the host immune
response toE.cuniculi,ashasbeendemonstratedforT. gondii
[79], or RWJ67657 could have therapeutic oﬀ-target eﬀects
in either the host or parasite. Better understandings of the
mechanism of action in this case will further help drug
development.
A large number of p38 MAPK inhibitors have recently
progressed into phase I and II clinical trials, thus providingJournal of Signal Transduction 13
basic inhibitor pharmacophores that can be modiﬁed to
target critical protozoan MAPKs speciﬁcally while at the
same time having less host toxicity (a problem with many
agents in the pyridinylimidazole class).
5.Conclusions
MAPKs play essential roles in virtually all eukaryotes.
Thus, inhibiting protozoan MAPK functions represents a
scientiﬁcally sound approach to developing novel classes
of antiprotozoan agents. As protozoan MAPKs are only
distantly related to mammalian MAPKs and have dis-
tinct active sites, it is reasonable to expect that selec-
tive agents can be developed to target pathogen pro-
teins with minimal collateral eﬀects on human counter-
parts.
Although only a very modest body of work on the
structure and functionofprotozoan MAPKscurrently exists,
the available evidence already suggests the general utility of
inhibiting protozoan parasite MAPK function as a treatment
strategy. Several speciﬁc MAPK candidates have also already
emergedfrom such work.Asinterest inMAPKsincreases, the
rateofimportantdiscoveriesandtheirpreclinicalandclinical
translation will also increase.
Speciﬁc roles for MAPKs cannot be predicted based
solely on sequence similarity to protein homologues. For
example, P. falciparum MAPK Pfmap-2 is essential for
the completion of asexual replication in human erythro-
cytes [48] and yet its closest homologue in P. berghei,
Pbmap-2 (with 93% amino acid sequence identity within
its catalytic domains to Pfmap-2 [80]), is dispensable
for both asexual replication and gametocyte formation in
the mouse erythrocyte. Pbmap-2 instead plays a critical
role in exﬂagellation in the mosquito midgut [81]. Thus,
while the structure of the MAPKs themselves remains
highly evolutionarily constrained even among closely related
Plasmodium species, the circuitry of the various signal
transduction pathways themselves has undergone signiﬁcant
divergent evolution. Therefore it is critical to establish
speciﬁc roles of particular MAPKs prior to drug develop-
ment.
Once the function of a MAPK from a pathogenic
protozoan parasite has been established, one can exploit
the phylogenetic diﬀerences between MAPKs of protozoan
and metazoan origin to design speciﬁc MAPK inhibitors.
Reﬁning the structure of human MAPK inhibitor pharma-
cophores already in existence should speed development
of new MAPK-inhibiting antiprotozoan drugs. We also
expect to see additional new classes of drugs developed,
which will be aided by additional structure/function studies.
Targeting upstream MAPK regulators is an approach that
also bears investigation, but which will likely lag owing to
signiﬁcant current knowledge gaps in understanding these
regulators.
A considerable challenge is to persevere with such
research giventhe relativelyscant resources availableforsuch
work, in spite of the fact that over one-half billion people
in many of the poorest parts of the world are infected by
pathogenic protozoan parasites [82].
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